Q-omics provides the consensus-scored SMIM17 profile across patient tissues and cancer cell-line models. SMIM17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SMIM17 is differentially expressed in 7, with the highest sampling consensus in CHOL. Additionally, SMIM17 RNA expression shows 19,781 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, CHOL, and THYM as cancer lineages where SMIM17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM17 survival associations across molecular data types. SMIM17 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM17 RNA expression–survival associations across cancer types. High SMIM17 expression shows unfavorable associations in MESO, LUSC, UCEC and SCLC, but favorable associations in LUAD and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SMIM17 RNA expression.
This table summarizes SMIM17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM17 shows lower tumor expression in LUAD, BLCA and KIRP and higher tumor expression in CHOL, KIRC and LIHC. The CHOL box plot shows higher SMIM17 RNA expression in tumor versus normal tissue (log2 FC = +0.688, t-test p < 0.001).
This table shows molecular features associated with SMIM17 in patient tissues and cancer cell lines. In patient samples, SMIM17 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
